Of oats, blocks cell cycle progression in vascular smooth muscle cells. Free Radic Biol Med 2006, 41:70208. Guo W, Nie L, Wu D, Smart ML, Collins FW, Meydani SN, Meydani M: Avenanthramides inhibit proliferation of human colon cancer cell lines in vitro. Nutr Cancer 2010, 62:1007016. Azuma H, Banno K, Yoshimura T: Pharmacological properties of N-(three,4dimethoxycinnamoyl) anthranilic acid (N-5), a brand new anti-atopic agent. Br J Pharmacol 1976, 58:48388. Isaji M, Miyata H, Ajisawa Y: Tranilast: a brand new application in the cardiovascular field as an antiproliferative drug. Cardiovasc Drug Rev 1998, 16:28899. Suzawa H, Kikuchi S, Ichikawa K, Koda A: Inhibitory action of Tranilast, an anti-allergic drug, on the release of cytokines and PGE2 from human monocytes-macrophages. Jpn J Pharmacol 1992, 60:850. Crittenden DB, Pillinger MH: The year in gout – 2010011. Bull NYU Hosp Jt Dis 2011, 69:25763. Inglis JJ, Criado G, Andrews M, Feldmann M, Williams RO, Selley ML: The anti-allergic drug, N-(three,4-dimethoxycinnamonyl) anthranilic acid, exhibits potent anti-inflammatory and analgesic properties in arthritis. Rheumatology 2007, 46:1428432. Platten M, Ho PP, Youssef S, Fontoura P, Garren H, Hur EM, Gupta R, Lee LY, Kidd BA, Robinson WH, Sobel RA, Selley ML, Steinman L: Treatment of autoimmune neuroinflammation using a synthetic tryptophan metabolite. Science 2005, 310:85055. Rogosnitzky M, Danks R, Kardash E: Therapeutic Prospective of Tranilast, an Anti-allergy Drug, in Proliferative Disorders. Anticancer Res 2012, 32:2471478.26. Zammit SC, Cox AJ, Gow RM, Zhang Y, Gilbert RE, Krum H, Kelly DJ, Williams SJ: Evaluation and optimization of antifibrotic activity of cinnamoyl anthranilates.Nitrendipine Bioorg Med Chem Lett 2009, 19:7003006.Anti-Mouse NK1.1 Antibody 27. Zhang Y, Edgley AJ, Cox AJ, Powell AK, Wang B, Kompa AR, Stapleton DI, Zammit SC, Williams SJ, Krum H, Gilbert RE, Kelly DJ: FT011, a new antifibrotic drug, attenuates fibrosis and chronic heart failure in experimental diabetic cardiomyopathy. Eur J Heart Fail 2012, 14:54962. 28. Zhang Y, Elsik M, Edgley AJ, Cox AJ, Kompa AR, Wang B, Tan CY, Khong FL, Stapleton DI, Zammit S, Williams SJ, Gilbert RE, Krum H, Kelly DJ: A brand new anti-fibrotic drug attenuates cardiac remodeling and systolic dysfunction following experimental myocardial infarction.PMID:23557924 Int J Cardio 2012. doi:ten.1016/j.icard.2012.11.067. PMID:23219315. 29. Tan SM, Zhang Y, Wang B, Tan CY, Zammit SC, Williams SJ, Krum H, Kelly DJ: An orally active anti-fibrotic compound, FT23, attenuates structural and functional abnormalities in an experimental model of diabetic cardiomyopathy. Clin Exp Pharmacol Physiol 2012, 39:65056. 30. Gilbert RE, Zhang Y, Williams SJ, Zammit SC, Stapleton DI, Cox AJ, Krum H, Langham R, Kelly DJ: A purpose-synthesised anti-fibrotic agent attenuates experimental kidney illnesses in the rat. PLoS A single 2012, 7:e47160. 31. Keasling JD: Manufacturing molecules via metabolic engineering. Science 2010, 330:1355358. 32. Pickens LB, Tang Y, Chooi YH: Metabolic engineering for the production of natural goods. Annu Rev Chem Biomol Eng 2011, 2:21136. 33. Williams SJ, Stapleton D, Zammit S, James D, Ernest R, Krum H: Therapeutic compounds. Usa: Patent Application No. 2010/0130497 A1; 2010. 34. Fielder DA, Redmond MJ, Cottrell IW: Avenanthramide-containing compositions. United states: Patent Application No. 2010/0267662 A1; 2010. 35. Yang Q, Reinhard K, Schiltz E, Matern U: Characterization and heterologous expression of hydroxycinnamoyl/benzoyl-CoA:anthranila.